The efficacy of antiretroviral agents approved for the treat-ment of HIV-1 infection is limited by the virus’s ability to develop resistance. As such there is an urgent need for new ways of thinking about anti-HIV drug development, and accordingly novel viral and cellular targets critical toHIV-1 replication need to be explored and exploited. The retroviral RNA genome encodes for three enzymes essential for viral replication: HIV-1 protease (PR), HIV-1 reverse transcrip-tase (RT) and HIV-1 integrase (IN). .
